PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22982177-8 2013 Treatments with GLP-1, exenatide, glyburide, nateglinide and sitagliptin effectively increased plasma human C-peptide levels and improved postprandial glucose concentrations. Nateglinide 45-56 insulin Homo sapiens 108-117 26417414-8 2015 Then, insulin secretion relative to glucose elevation (ISG) (DeltaISG0-180 min: DeltaAUC0-180 min insulin/AUC0-180 min glucose) was significantly enhanced by nateglinide compared with sitagliptin. Nateglinide 158-169 insulin Homo sapiens 98-105 23631607-11 2013 Moreover, the nateglinide-treated group had significantly increased insulin levels at 30 min and at 120 min after a standard meal compared with baseline, whereas the acarbose-treated group decreased. Nateglinide 14-25 insulin Homo sapiens 68-75 26734075-9 2016 Nateglinide was associated with higher insulin and pro-insulin secretion, but similar pro-insulin/insulin ratio when compared with rosiglitazone. Nateglinide 0-11 insulin Homo sapiens 39-46 26734075-9 2016 Nateglinide was associated with higher insulin and pro-insulin secretion, but similar pro-insulin/insulin ratio when compared with rosiglitazone. Nateglinide 0-11 insulin Homo sapiens 55-62 26734075-9 2016 Nateglinide was associated with higher insulin and pro-insulin secretion, but similar pro-insulin/insulin ratio when compared with rosiglitazone. Nateglinide 0-11 insulin Homo sapiens 55-62 26734075-9 2016 Nateglinide was associated with higher insulin and pro-insulin secretion, but similar pro-insulin/insulin ratio when compared with rosiglitazone. Nateglinide 0-11 insulin Homo sapiens 55-62 26548081-4 2015 In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model. Nateglinide 187-198 insulin Homo sapiens 159-166 26417414-8 2015 Then, insulin secretion relative to glucose elevation (ISG) (DeltaISG0-180 min: DeltaAUC0-180 min insulin/AUC0-180 min glucose) was significantly enhanced by nateglinide compared with sitagliptin. Nateglinide 158-169 insulin Homo sapiens 6-13 25560470-1 2015 Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Nateglinide 33-44 insulin Homo sapiens 84-91 25560470-1 2015 Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Nateglinide 33-44 insulin Homo sapiens 142-149 24461109-10 2014 On day 7, compared with pasireotide alone, the decrease in serum insulin was attenuated with nateglinide, metformin, liraglutide and vildagliptin co-administration (levels were 3%, 6%, 34% and 71% higher, respectively). Nateglinide 93-104 insulin Homo sapiens 65-72 21548456-1 2011 Meglitinides (repaglinide and nateglinide) are insulin secretagogues used to treat diabetes mellitus. Nateglinide 30-41 insulin Homo sapiens 47-54 21801074-3 2011 Nateglinide, a short-acting insulin secretagogue of the meglitinide class of antidiabetic agents, has been marketed for the past decade specifically to address the diminished postprandial insulin secretion. Nateglinide 0-11 insulin Homo sapiens 28-35 21801074-3 2011 Nateglinide, a short-acting insulin secretagogue of the meglitinide class of antidiabetic agents, has been marketed for the past decade specifically to address the diminished postprandial insulin secretion. Nateglinide 0-11 insulin Homo sapiens 188-195 22727067-1 2012 BACKGROUND: Nateglinide, N-(trans-4-isopropylcyclohexyl-carbonyl)-d-phenylalanine, is a potent insulin secretagogue designed to restore early-phase insulin secretion. Nateglinide 12-23 insulin Homo sapiens 95-102 22727067-1 2012 BACKGROUND: Nateglinide, N-(trans-4-isopropylcyclohexyl-carbonyl)-d-phenylalanine, is a potent insulin secretagogue designed to restore early-phase insulin secretion. Nateglinide 12-23 insulin Homo sapiens 148-155 22727067-1 2012 BACKGROUND: Nateglinide, N-(trans-4-isopropylcyclohexyl-carbonyl)-d-phenylalanine, is a potent insulin secretagogue designed to restore early-phase insulin secretion. Nateglinide 25-81 insulin Homo sapiens 95-102 22727067-1 2012 BACKGROUND: Nateglinide, N-(trans-4-isopropylcyclohexyl-carbonyl)-d-phenylalanine, is a potent insulin secretagogue designed to restore early-phase insulin secretion. Nateglinide 25-81 insulin Homo sapiens 148-155 21185798-1 2011 The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. Nateglinide 11-22 insulin Homo sapiens 149-156 21185798-1 2011 The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. Nateglinide 117-128 insulin Homo sapiens 149-156 19755410-1 2009 BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. Nateglinide 12-23 insulin Homo sapiens 45-52 20334663-11 2010 Area under the curve (AUC) for insulin response was significantly increased in the nateglinide and control groups; however, no significant change was observed in the acarbose group. Nateglinide 83-94 insulin Homo sapiens 31-38 20865534-7 2010 Nateglinide and Glimepiride are a class of insulin secretagog agents that lowers blood glucose levels by stimulating insulin secretion from the pancreas. Nateglinide 0-11 insulin Homo sapiens 43-50 20865534-7 2010 Nateglinide and Glimepiride are a class of insulin secretagog agents that lowers blood glucose levels by stimulating insulin secretion from the pancreas. Nateglinide 0-11 insulin Homo sapiens 117-124 17587398-0 2007 Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Nateglinide 61-72 insulin Homo sapiens 15-22 18792871-8 2008 Insulin concentrations increased while glucose concentrations decreased on study-days with nateglinide when compared to study-days without (p=<0.001 for both insulin and glucose). Nateglinide 91-102 insulin Homo sapiens 0-7 30780794-3 2009 Nateglinide is a rapid-onset, short-acting insulin-secretion enhancer that restores early-phase insulin secretion, reduces postprandial glucose excursions and prevents long-term hyperinsulinemia. Nateglinide 0-11 insulin Homo sapiens 43-50 30780794-4 2009 Given its mechanism of action, it is evident that nateglinide would be more effective when used in combination with an insulin sensitizer, such as the thiazolidinediones. Nateglinide 50-61 insulin Homo sapiens 119-126 17316868-3 2007 Chronic exposure of pancreatic beta-cells to sulfonylureas (glibenclamide or tolbutamide) and glinide (nateglinide) similarly impaired their acute effectiveness by reducing the insulin content and the number of functional K(ATP) channels on the plasma membrane. Nateglinide 103-114 insulin Homo sapiens 177-184 17587398-12 2007 The effects of nateglinide on AUC of BG, insulin and CP were similar to that of repaglinide (p > 0.05). Nateglinide 15-26 insulin Homo sapiens 41-48 17587398-12 2007 The effects of nateglinide on AUC of BG, insulin and CP were similar to that of repaglinide (p > 0.05). Nateglinide 15-26 insulin Homo sapiens 53-55 17587398-19 2007 This trial had shown that nateglinide and repaglinide could comparably improve insulin sensitivity and beta-cell function. Nateglinide 26-37 insulin Homo sapiens 79-86 17376293-5 2007 Compared to acarbose, nateglinide significantly increased postprandial insulin release after a standard meal test in patients with type 2 diabetes. Nateglinide 22-33 insulin Homo sapiens 71-78 17376293-9 2007 CONCLUSION: These results suggest that the reduction of postprandial FFA and ADMA concentrations induced by nateglinide may be associated with the partial restoration of early-phase insulin secretion and may impart a cardiovascular advantage in comparison with acarbose. Nateglinide 108-119 insulin Homo sapiens 182-189 17298589-1 2007 OBJECTIVE: To determine the effect of adding nateglinide to therapy with insulin glargine in adults with Type 2 diabetes previously treated with insulin and with poor blood glucose control. Nateglinide 45-56 insulin Homo sapiens 73-80 17298589-1 2007 OBJECTIVE: To determine the effect of adding nateglinide to therapy with insulin glargine in adults with Type 2 diabetes previously treated with insulin and with poor blood glucose control. Nateglinide 45-56 insulin Homo sapiens 145-152 17425753-3 2007 Nateglinide is a rapid acting insulin secretagogue inducing an EIR after a meal. Nateglinide 0-11 insulin Homo sapiens 30-37 17425753-10 2007 CONCLUSIONS: Treating RTR with nateglinide for two-wk significantly improved PPHG, increased the insulin response following a standardized meal and was well tolerated. Nateglinide 31-42 insulin Homo sapiens 97-104 17003289-3 2006 GLP-1 similarly augmented the K(ATP) channel-independent insulin-releasing effects of tolbutamide, glibenclamide or nateglinide. Nateglinide 116-127 insulin Homo sapiens 57-64 17298589-7 2007 CONCLUSIONS: Addition of nateglinide before meals to once-daily insulin glargine in people with long-standing diabetes already requiring insulin therapy improves blood glucose control in the early part of the day after breakfast and lunch, but does not provide good control of blood glucose levels overall. Nateglinide 25-36 insulin Homo sapiens 137-144 17003289-6 2006 The synergistic insulin-releasing effects of combinatorial GLP-1 and sulphonylurea/nateglinide were lost following PKA- or PKC-desensitisation, despite GLP-1 retaining an insulin-releasing effect, demonstrating that GLP-1 can induce insulin release under conditions where sulphonylureas and nateglinide are no longer effective. Nateglinide 83-94 insulin Homo sapiens 16-23 16842480-9 2006 Postprandial insulin levels were significantly higher with nateglinide compared with gliclazide. Nateglinide 59-70 insulin Homo sapiens 13-20 17050498-9 2006 The results of the present study show that nateglinide is effective in controlling blood glucose and improving insulin resistance, hypertriglyceridemia, and LDL particle size in patients with mild type 2 diabetes. Nateglinide 43-54 insulin Homo sapiens 111-118 16260353-0 2005 Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals. Nateglinide 49-60 insulin Homo sapiens 64-71 16214255-0 2006 Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Nateglinide 22-33 insulin Homo sapiens 37-44 16214255-1 2006 Nateglinide, a rapid insulin secretagogue, is known to facilitate the early phase of insulin secretion and has been used for the treatment of type 2 diabetic patients with postprandial hyperglycemia. Nateglinide 0-11 insulin Homo sapiens 21-28 16214255-2 2006 The aim of this study is to evaluate the effect of nateglinide on insulin resistance as well as insulin secretory defects in type 2 diabetic patients. Nateglinide 51-62 insulin Homo sapiens 66-73 16214255-6 2006 Moreover, in the euglycemic hyperinsulinemic clamp test, glucose infusion rate was significantly increased by nateglinide treatment, indicating that nateglinide functions to decrease insulin resistance. Nateglinide 110-121 insulin Homo sapiens 33-40 16214255-6 2006 Moreover, in the euglycemic hyperinsulinemic clamp test, glucose infusion rate was significantly increased by nateglinide treatment, indicating that nateglinide functions to decrease insulin resistance. Nateglinide 149-160 insulin Homo sapiens 33-40 16214255-7 2006 Nateglinide ameliorates insulin resistance as well as insulin secretory defects in type 2 diabetic patients. Nateglinide 0-11 insulin Homo sapiens 24-31 16443858-1 2006 OBJECTIVE: To study the effect of the short-acting insulin secretagogue nateglinide in patients with maturity-onset diabetes of the young type 3 (MODY3), which is characterized by a defective insulin response to glucose and hypersensitivity to sulfonylureas. Nateglinide 72-83 insulin Homo sapiens 51-58 16443858-2 2006 RESEARCH DESIGN AND METHODS: We compared the acute effect of nateglinide, glibenclamide, and placebo on prandial plasma glucose and serum insulin, C-peptide, and glucagon excursions in 15 patients with MODY3. Nateglinide 61-72 insulin Homo sapiens 138-145 16443858-4 2006 RESULTS: Insulin peaked earlier after nateglinide than after glibenclamide or placebo (median [interquartile range] time 70 [50] vs. 110 [20] vs. 110 [30] min, P = 0.0002 and P = 0.0025, respectively). Nateglinide 38-49 insulin Homo sapiens 9-16 16443858-6 2006 The improved prandial glucose control with nateglinide was achieved with a lower peak insulin concentration than after glibenclamide (47.0 [26.0] vs. 80.4 [71.7] mU/l; P = 0.023). Nateglinide 43-54 insulin Homo sapiens 86-93 16443858-8 2006 CONCLUSIONS: A low dose of nateglinide prevents the acute postprandial rise in glucose more efficiently than glibenclamide and with less stimulation of peak insulin concentrations and less hypoglycemic symptoms. Nateglinide 27-38 insulin Homo sapiens 157-164 16260353-1 2005 BACKGROUND: Nateglinide is a D-phenylalanine derivative that stimulates fast insulin secretion with a short activity span. Nateglinide 12-23 insulin Homo sapiens 77-84 16260353-3 2005 OBJECTIVE: The aim of this study is to evaluate the effect of nateglinide on the insulin secretion at two different concentrations of glucose level. Nateglinide 62-73 insulin Homo sapiens 81-88 16260353-6 2005 RESULTS: In volunteers submitted to the clamp at 4.1 mmol/l above the baseline of glucose level, the insulin secretion in the early phase was 212.4+/-55.8 pmol/l in the placebo test versus 338.4+/-124.8 pmol/l in the nateglinide test (P<.05), whereas in the group submitted at 6.9 mmol/l over the baseline, no significant differences were observed. Nateglinide 217-228 insulin Homo sapiens 101-108 16260353-7 2005 CONCLUSION: Nateglinide increased the early insulin secretion in healthy individuals submitted to a mild hyperglycemia, but not at high glucose concentrations. Nateglinide 12-23 insulin Homo sapiens 44-51 15724236-6 2005 RESULTS: The 1-h insulin levels during the meal tolerance test were significantly higher with nateglinide (577 +/- 81 vs 376 +/- 58 pmol L(-1), p < 0.001), as well as the response during the first two hours (IAUC: 41 243 +/- 5844 vs 29 956 +/- 4662 pmol L(-1) min, p < 0.01). Nateglinide 94-105 insulin Homo sapiens 17-24 16178991-2 2005 Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin secretion in a transient and glucose-sensitive manner without affecting basal insulin levels. Nateglinide 0-11 insulin Homo sapiens 77-84 16178991-5 2005 The combination of nateglinide with insulin-sensitising agents, for example, metformin and thiazolidinediones, addresses the dual defects of loss of insulin secretion and insulin resistance to provide optimal management of type 2 diabetes, and more patients achieve HbA 1c goal with nateglinide combination therapy rather than with monotherapy with other oral agents. Nateglinide 283-294 insulin Homo sapiens 36-43 15871845-10 2005 Plasma insulin levels were significantly higher after nateglinide than after placebo (P=0.002). Nateglinide 54-65 insulin Homo sapiens 7-14 15986773-1 2005 Nateglinide is a novel rapid- and short-acting insulin secretagogue that ameliorates postprandial hyperglycemia by improving insulin secretory dynamics to a near normal level more effectively than sulfonylureas. Nateglinide 0-11 insulin Homo sapiens 47-54 15986773-1 2005 Nateglinide is a novel rapid- and short-acting insulin secretagogue that ameliorates postprandial hyperglycemia by improving insulin secretory dynamics to a near normal level more effectively than sulfonylureas. Nateglinide 0-11 insulin Homo sapiens 125-132 15715891-1 2005 AIM: The aim of this study was to investigate the influence of changes in insulin resistance and early insulin secretion on the insulin secretagogic effects of nateglinide. Nateglinide 160-171 insulin Homo sapiens 74-81 15715891-1 2005 AIM: The aim of this study was to investigate the influence of changes in insulin resistance and early insulin secretion on the insulin secretagogic effects of nateglinide. Nateglinide 160-171 insulin Homo sapiens 103-110 15715891-7 2005 CONCLUSION: Insulin response to nateglinide after glucose loading varied greatly in conjunction with weight loss. Nateglinide 32-43 insulin Homo sapiens 12-19 15715891-8 2005 This may be accounted for not only by the enhancement of early insulin response to nateglinide associated with the improvement of early insulin response with weight loss but also by the reduced visceral fat, which in turn led to reduced levels of free fatty acids in portal blood and hepatic triglycerides, as well as increased hepatic insulin clearance. Nateglinide 83-94 insulin Homo sapiens 63-70 15715891-8 2005 This may be accounted for not only by the enhancement of early insulin response to nateglinide associated with the improvement of early insulin response with weight loss but also by the reduced visceral fat, which in turn led to reduced levels of free fatty acids in portal blood and hepatic triglycerides, as well as increased hepatic insulin clearance. Nateglinide 83-94 insulin Homo sapiens 136-143 15155541-0 2004 Acute and long-term effects of nateglinide on insulin secretory pathways. Nateglinide 31-42 insulin Homo sapiens 46-53 15375790-9 2004 Plasma insulin levels were significantly higher from 100 to 240 minutes after clamp termination in patients given glyburide versus nateglinide. Nateglinide 131-142 insulin Homo sapiens 7-14 15317602-1 2004 AIMS: This randomized crossover placebo-controlled study aimed to assess the efficacy of nateglinide, a phenylalanine-derived insulin secretagogue, on forearm endothelial function in diabetic subjects before and after an oral glucose load. Nateglinide 89-100 insulin Homo sapiens 126-133 15155541-2 2004 Nateglinide (10-400 microm) stimulated a concentration-dependent increase (P<0.05-P<0.001) in insulin release at a non-stimulatory (1.1 mm) glucose concentration. Nateglinide 0-11 insulin Homo sapiens 100-107 14746575-5 2004 RESULTS: Mean peak serum insulin levels were lower after nateglinide (115 mU/l) than after glibenclamide (145 mU/l.h; p = 0.017) but higher than after placebo (79 mU/l; p = 0.001). Nateglinide 57-68 insulin Homo sapiens 25-32 15133755-6 2004 RESULTS: Neutrophil-transendothelial migration and PECAM-1 expression were enhanced by insulin (100 micro U/mL, 24 h) and were attenuated by gliclazide (20 micro M), but not by other K(ATP) channel blockers (glibenclamide, nateglinide, and glimepiride). Nateglinide 223-234 insulin Homo sapiens 87-94 14746575-6 2004 However, peak insulin levels were reached earlier after nateglinide [mean time to peak (tmax) 1.7 h] compared to glibenclamide (mean tmax 2.1 h, p = 0.06). Nateglinide 56-67 insulin Homo sapiens 14-21 14746575-10 2004 CONCLUSIONS: Nateglinide improves early prandial measures of insulin and glucose response to a standard meal, more so than glibenclamide, in people with type 2 diabetes. Nateglinide 13-24 insulin Homo sapiens 61-68 14581145-0 2003 Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model. Nateglinide 65-76 insulin Homo sapiens 15-22 15005635-3 2004 OBJECTIVE: To assess the impact of CYP2C9 polymorphisms and of the CYP2D6 poor metaboliser genotype on the pharmacokinetics of nateglinide and its effects on insulin, glucose and glucagon in plasma. Nateglinide 127-138 insulin Homo sapiens 158-165 15058753-4 2003 After glucose loading, insulin levels increased significantly at 30, 60, 90, and 120 minutes after the patients took nateglinide, along with insulinogenic indices, the total area under the insulin curve, the area under the 0- to 90-minute insulin curve, and the area under the 90- to 180-minute insulin curve. Nateglinide 117-128 insulin Homo sapiens 23-30 15058753-7 2003 Nateglinide demonstrated a rapid-onset and rapid-offset insulin secretion-stimulating effect in this study population. Nateglinide 0-11 insulin Homo sapiens 56-63 14748619-13 2004 The postprandial insulinotropic effects of nateglinide are more rapid than those of repaglinide and more rapid and greater than those of glibenclamide (glyburide), while producing less prolonged insulin exposure and less risk of delayed hypoglycaemia. Nateglinide 43-54 insulin Homo sapiens 17-24 14709397-7 2004 RESULTS: Both neutrophil adhesion and ICAM-1 expression enhanced by high insulin (100 microU/ml, 48 h) were attenuated by gliclazide (20 microM), but not by other K(ATP) channel blockers (glibenclamide, nateglinide, and glimepiride). Nateglinide 203-214 insulin Homo sapiens 73-80 14581145-0 2003 Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model. Nateglinide 65-76 insulin Homo sapiens 43-50 14581145-2 2003 A new insulin secretagogue, nateglinide, has been shown to elicit an acute insulin release and to reduce postprandial hyperglycemia. Nateglinide 28-39 insulin Homo sapiens 6-13 14581145-2 2003 A new insulin secretagogue, nateglinide, has been shown to elicit an acute insulin release and to reduce postprandial hyperglycemia. Nateglinide 28-39 insulin Homo sapiens 75-82 14581145-11 2003 In conclusion, nateglinide improved the excessive excursion of postprandial glucose by the augmentation of early insulin secretion after a meal and differentially affected fasting insulin levels and HOMA-IR indexes, depending on the degree of insulin resistance. Nateglinide 15-26 insulin Homo sapiens 113-120 14581145-11 2003 In conclusion, nateglinide improved the excessive excursion of postprandial glucose by the augmentation of early insulin secretion after a meal and differentially affected fasting insulin levels and HOMA-IR indexes, depending on the degree of insulin resistance. Nateglinide 15-26 insulin Homo sapiens 180-187 12965106-5 2003 RESULTS: Plasma glucose and glycated insulin responses were reduced by 9% (P=0.005) and 38% (P=0.047), respectively, following nateglinide compared with placebo. Nateglinide 127-138 insulin Homo sapiens 37-44 12965106-6 2003 Corresponding AUC measures for insulin and C-peptide were enhanced by 36% (P=0.005) and 25% (P=0.007) by nateglinide. Nateglinide 105-116 insulin Homo sapiens 31-38 12965106-7 2003 CONCLUSIONS: Glycated insulin in type 2 diabetes is reduced in response to the insulin secretagogue nateglinide, resulting in preferential release of native insulin. Nateglinide 100-111 insulin Homo sapiens 22-29 12965106-7 2003 CONCLUSIONS: Glycated insulin in type 2 diabetes is reduced in response to the insulin secretagogue nateglinide, resulting in preferential release of native insulin. Nateglinide 100-111 insulin Homo sapiens 79-86 12965106-7 2003 CONCLUSIONS: Glycated insulin in type 2 diabetes is reduced in response to the insulin secretagogue nateglinide, resulting in preferential release of native insulin. Nateglinide 100-111 insulin Homo sapiens 79-86 12965106-8 2003 Since glycated insulin exhibits impaired biological activity, reduced glycated insulin release may contribute to the antihyperglycaemic action of nateglinide. Nateglinide 146-157 insulin Homo sapiens 15-22 12965106-8 2003 Since glycated insulin exhibits impaired biological activity, reduced glycated insulin release may contribute to the antihyperglycaemic action of nateglinide. Nateglinide 146-157 insulin Homo sapiens 79-86 12940610-5 2003 RESULTS: After a single 90 mg dose, nateglinide significantly increased the post-prandial secretion of insulin and thereby reduced plasma glucose levels. Nateglinide 36-47 insulin Homo sapiens 103-110 12766094-9 2003 In nateglinide-treated patients, fasting plasma glucose levels decreased by 0.7 mmol/l, 2-h postprandial glucose levels decreased by 2.7 mmol/l, and 30-min insulin levels increased by 165 pmol/l compared with no changes from baseline of these parameters with placebo added to rosiglitazone (P < 0.001). Nateglinide 3-14 insulin Homo sapiens 156-163 12877088-6 2003 Nateglinide, a rapidly acting insulin secretagogue, lowers postprandial glucose levels without significant body weight gain. Nateglinide 0-11 insulin Homo sapiens 30-37 12860494-13 2003 Insulin T(max) was shorter after nateglinide administration at -30 or -10 minutes, which was associated with lower glucose C(max) values (-30 minutes, P < 0.05) and a tendency for lower glucose AUC(0-5) values (-10 minutes, P = NS). Nateglinide 33-44 insulin Homo sapiens 0-7 12453951-6 2002 RESULTS: Nateglinide elicited a dose-related increase of insulin and a decrease of glucose during standardized meal challenges, with the predominant effect on early insulin release, leading to a substantial reduction in peak plasma glucose levels. Nateglinide 9-20 insulin Homo sapiens 57-64 12652357-3 2003 Nateglinide mediates the release of insulin from beta-cells by binding to the sulphonylurea receptors, which leads to the closure of ATP-sensitive K(+) channels. Nateglinide 0-11 insulin Homo sapiens 36-43 12652357-4 2003 Increasing evidence from receptor binding, mechanistic and in vitro and in vivo insulin studies indicate unique pharmacodynamic and pharmacokinetic properties with nateglinide that are distinct from those of sulphonylureas. Nateglinide 164-175 insulin Homo sapiens 80-87 12652357-9 2003 Given that the kinetic profile of the agent is associated with selective enhancement of early-phase insulin secretion, nateglinide is expected to minimise post-meal hyperglycaemia with minimal propensity for hypoglycaemia. Nateglinide 119-130 insulin Homo sapiens 100-107 12189909-9 2002 Prandial oral antidiabetic agents such as alpha-glucosidase inhibitors (acarbose, miglitol) and rapidly acting insulin secretagogues (nateglinide, repaglinide) have recently been introduced to improve the control of post-prandial hyperglycemia. Nateglinide 134-145 insulin Homo sapiens 111-118 12196472-1 2002 Repaglinide and nateglinide represent a new class of insulin secretagogues, structurally unrelated to sulphonylureas, that were developed for the treatment of type 2 diabetes. Nateglinide 16-27 insulin Homo sapiens 53-60 12625415-0 2002 The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects. Nateglinide 15-26 insulin Homo sapiens 101-108 12625415-0 2002 The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects. Nateglinide 124-135 insulin Homo sapiens 101-108 12625415-1 2002 This study was designed to determine the effect of a novel insulin secretagogue, nateglinide, on the glycemic response curve and early insulin secretion following oral glucose load in impaired glucose tolerance (IGT) subjects. Nateglinide 81-92 insulin Homo sapiens 59-66 12625415-5 2002 Nateglinide administration resulted in the almost normalization of the glycemic response curve with restoration of impairment in early insulin response at 30 and 60 min after an oral glucose load. Nateglinide 0-11 insulin Homo sapiens 135-142 12625415-7 2002 A single dose of nateglinide was shown to almost normalize the glycemic response curve after a 75 g OGTT and to restore impairment in early insulin response in IGT subjects. Nateglinide 17-28 insulin Homo sapiens 140-147 12419950-8 2002 Plasma insulin levels were significantly increased at 30 min in nateglinide-treated rats, but not in voglibose- or glibenclamide-treated rats. Nateglinide 64-75 insulin Homo sapiens 7-14 12213867-1 2002 Nateglinide is a fast-acting insulin secretion agent that specifically targets postprandial hyperglycemia in patients with type 2 diabetes. Nateglinide 0-11 insulin Homo sapiens 29-36 12213867-6 2002 Nateglinide increased early insulin release and reduced prandial glucose excursions (P < 0.05 vs. placebo). Nateglinide 0-11 insulin Homo sapiens 28-35 11739446-5 2001 Insulin release commenced immediately after nateglinide administration, even before glucose injection, but this was not observed with glyburide. Nateglinide 44-55 insulin Homo sapiens 0-7 11782867-0 2002 Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion. Nateglinide 36-47 insulin Homo sapiens 90-97 11782867-1 2002 Nateglinide is a new, fast-onset, short-acting hypoglycemic agent, which increases early phase insulin secretion and the total amount of insulin secreted. Nateglinide 0-11 insulin Homo sapiens 95-102 12073790-6 2002 A more physiological post-meal profile of insulin may be obtained in type 2 diabetes by using new insulin secretagogues of the glinide family (repaglinide, nateglinide) with an earlier and shorter insulinotropic action or, mainly in type 1 diabetes but also in type 2 diabetes, by using short-acting insulin analogues (lispro. Nateglinide 156-167 insulin Homo sapiens 42-49 12073790-6 2002 A more physiological post-meal profile of insulin may be obtained in type 2 diabetes by using new insulin secretagogues of the glinide family (repaglinide, nateglinide) with an earlier and shorter insulinotropic action or, mainly in type 1 diabetes but also in type 2 diabetes, by using short-acting insulin analogues (lispro. Nateglinide 156-167 insulin Homo sapiens 98-105 12073790-6 2002 A more physiological post-meal profile of insulin may be obtained in type 2 diabetes by using new insulin secretagogues of the glinide family (repaglinide, nateglinide) with an earlier and shorter insulinotropic action or, mainly in type 1 diabetes but also in type 2 diabetes, by using short-acting insulin analogues (lispro. Nateglinide 156-167 insulin Homo sapiens 98-105 11902096-2 2002 Combining metformin with the amino acid derivative, nateglinide, tackles both beta cell dysfunction and insulin resistance, and produces a greater decrease in haemoglobin A1c levels than treatment with either drug alone. Nateglinide 52-63 insulin Homo sapiens 104-111 11739446-6 2001 Both nateglinide and glyburide enhanced glucose-induced insulin release, compared with placebo (area under the curve -15-300 min: nateglinide 23,595 +/- 11,212 pM/min, glyburide 54,556 +/- 15,253 pM/min, placebo 10,242 +/- 2,414 pM/min). Nateglinide 5-16 insulin Homo sapiens 56-63 11739446-7 2001 The profiles of insulin release demonstrated significant enhancement of release between -15 and 30 min for nateglinide, compared with glyburide and between 60 and 300 min for glyburide over nateglinide. Nateglinide 107-118 insulin Homo sapiens 16-23 11739446-9 2001 The enhancement of insulin release by glyburide resulted in a lower minimal glucose concentration with glyburide (3.8 +/- 0.2 mM), compared with nateglinide (5.0 +/- 0.2 mM) and placebo (5.9 +/- 0.2 mM). Nateglinide 145-156 insulin Homo sapiens 19-26 11739446-11 2001 Further, the differences in the kinetics of nateglinide and glyburide action results in continued insulin release with glyburide despite the fact that glucose levels have returned to basal, thus resulting in a further reduction in glucose levels and a lower nadir. Nateglinide 44-55 insulin Homo sapiens 98-105 11547215-8 2001 As to new insulin secretagogues, the phenylalanine derivative nateglinide is a first phase insulin secretion enhancer primarily intended at controlling post-prandial hyperglycemia. Nateglinide 62-73 insulin Homo sapiens 10-17 11600556-7 2001 The impact on the glucose profile was consistent with the enhanced insulin profiles after nateglinide, resulting in higher peak plasma insulin concentrations compared with placebo (P < 0.01). Nateglinide 90-101 insulin Homo sapiens 67-74 11600556-7 2001 The impact on the glucose profile was consistent with the enhanced insulin profiles after nateglinide, resulting in higher peak plasma insulin concentrations compared with placebo (P < 0.01). Nateglinide 90-101 insulin Homo sapiens 135-142 11600556-10 2001 Preprandial administration of nateglinide was more effective in reducing prandial glucose excursions, compared with postmeal dosing (+10 min), a consequence of the earlier insulin response. Nateglinide 30-41 insulin Homo sapiens 172-179 11423506-1 2001 OBJECTIVE: This randomized crossover double-blind placebo-controlled study aimed to assess the efficacy of nateglinide (A-4166), a novel phenylalanine-derived insulin secretagogue, in type 2 diabetic subjects while fasting and 5 min before a standard meal. Nateglinide 107-118 insulin Homo sapiens 159-166 11449877-3 2001 Nateglinide, an amino acid derivative of D-phenylalanine, stimulates the secretion of insulin by binding to the ATP potassium channels in pancreatic beta cells. Nateglinide 0-11 insulin Homo sapiens 86-93 11565495-14 2001 Sulfonylureas and other insulin secretagogues (e.g., meglitinide, nateglinide) lower glucoses acutely. Nateglinide 66-77 insulin Homo sapiens 24-31 11375357-12 2001 h/l), but the insulin AUC induced by nateglinide was significantly less than that induced by glyburide ( 12-h AUC = +866 vs. +1,702 pmol. Nateglinide 37-48 insulin Homo sapiens 14-21 11375357-14 2001 CONCLUSIONS: This study demonstrated that nateglinide selectively enhanced early insulin release and provided better mealtime glucose control with less total insulin exposure than glyburide. Nateglinide 42-53 insulin Homo sapiens 81-88 11375357-14 2001 CONCLUSIONS: This study demonstrated that nateglinide selectively enhanced early insulin release and provided better mealtime glucose control with less total insulin exposure than glyburide. Nateglinide 42-53 insulin Homo sapiens 158-165 11194245-6 2001 RESULTS: Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval. Nateglinide 9-20 insulin Homo sapiens 29-36 12764427-5 2001 Thus, nateglinide has a rapid onset and short duration of action stimulating insulin secretion in vivo and providing good control of postprandial hyperglycemia when taken immediately prior to meals. Nateglinide 6-17 insulin Homo sapiens 77-84 12764427-6 2001 The rapid action of nateglinide on the beta cells stimulates and restores the normal physiological first and early phase of insulin secretion, consequently reducing postprandial hyperglycemia. Nateglinide 20-31 insulin Homo sapiens 124-131 12764427-10 2001 However, nateglinide"s effects on insulin secretion and glycemic control differ significantly from the sulfonylureas and repaglinide in that it preferentially stimulates acute phase insulin, better controls postprandial glucose excursions and spikes, and causes less hyperinsulinemia and hypoglycemia. Nateglinide 9-20 insulin Homo sapiens 34-41 12764427-10 2001 However, nateglinide"s effects on insulin secretion and glycemic control differ significantly from the sulfonylureas and repaglinide in that it preferentially stimulates acute phase insulin, better controls postprandial glucose excursions and spikes, and causes less hyperinsulinemia and hypoglycemia. Nateglinide 9-20 insulin Homo sapiens 182-189 12764427-12 2001 Clinical studies with nateglinide have confirmed that it acts rapidly and both restores insulin release and attenuates the postprandial glucose spike. Nateglinide 22-33 insulin Homo sapiens 88-95 11194245-7 2001 After peaking, insulin concentrations decreased rapidly in the nateglinide-treated group and were similar to placebo within 2 h postdose. Nateglinide 63-74 insulin Homo sapiens 15-22 11194245-13 2001 If similar results are observed in diabetes, nateglinide may produce a more physiological insulin secretory response with the potential for a reduced risk of postabsorptive hypoglycemia. Nateglinide 45-56 insulin Homo sapiens 90-97 11030470-1 2000 Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide 0-11 insulin Homo sapiens 189-196 11031747-5 2000 Nateglinide, which is a derivative of D-phenylalanine, is a non-sulfonylurea insulin secretagogue. Nateglinide 0-11 insulin Homo sapiens 77-84 11031747-6 2000 Although the in vitro insulin-releasing effect of nateglinide is similar to that of sulfonylureas, its hypoglycemic effect is more rapid and short lasting. Nateglinide 50-61 insulin Homo sapiens 22-29 11031747-9 2000 In clinical trials, nateglinide reduced prandial glucose excursion and improved early phase of insulin release dose-dependently after 12 weeks treatment. Nateglinide 20-31 insulin Homo sapiens 95-102 11031747-10 2000 Nateglinide is a highly physiologic mealtime glucose regulator, which rapidly increases insulin secretion when taken before meals, mimicking early-phase insulin release lost in patients with Type 2 diabetes. Nateglinide 0-11 insulin Homo sapiens 88-95 10784228-2 2000 This study examined whether nateglinide can enhance insulin secretion, and particularly the first phase insulin response, in patients with Type 2 diabetes. Nateglinide 28-39 insulin Homo sapiens 52-59 10784228-4 2000 RESULTS: Insulin secretion (both overall and first phase) was significantly increased by nateglinide (P < 0.001), as were C-peptide (P < 0.001) and proinsulin (P < 0.001) secretion. Nateglinide 89-100 insulin Homo sapiens 9-16 10784228-6 2000 CONCLUSIONS: Nateglinide significantly increases insulin secretion in Type 2 diabetic patients, in particular restoring the first phase insulin response. Nateglinide 13-24 insulin Homo sapiens 49-56 11563410-1 1999 Nateglinide (Starlix, SDZ DJN 608 or A-4166), a new insulinotropic agent, is intended to be administered prior to a meal in order to improve early insulin release in non-insulin-dependent diabetes mellitus patients. Nateglinide 0-11 insulin Homo sapiens 52-59 11563410-12 1999 Regardless of timing, the combination of a meal and nateglinide produced a larger increase in insulin levels than did nateglinide alone. Nateglinide 52-63 insulin Homo sapiens 94-101 11563410-14 1999 Thus, the rapid onset/short duration stimulation of insulin release by nateglinide should allow good control of prandial hyperglycemia while limiting exposure to hyperinsulinemia. Nateglinide 71-82 insulin Homo sapiens 52-59 9117089-2 1997 (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166), a novel oral hypoglycaemic agent is a non-sulphonylurea insulin secretagogue. Nateglinide 0-60 insulin Homo sapiens 127-134 11190420-7 2000 Repaglinide and nateglinide are absorbed rapidly, stimulate insulin release within a few minutes, are rapidly metabolised in the liver and are mainly excreted in the bile. Nateglinide 16-27 insulin Homo sapiens 60-67 11200947-0 2000 Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Nateglinide 183-194 insulin Homo sapiens 20-27 11200947-2 2000 The restoration of endogenous rapid insulin secretion after oral glucose load was established for the first time by using nateglinide, which is a newly developed insulin secretagogue, in obese patients with type 2 diabetes mellitus. Nateglinide 122-133 insulin Homo sapiens 36-43 11200947-3 2000 It was clearly demonstrated that with nateglinide, serum insulin levels were quickly raised, and glycemic response curves were almost normalized with the same amount of insulin secretion during 180 min. Nateglinide 38-49 insulin Homo sapiens 57-64 11030470-2 2000 Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (non-insulin-dependent) diabetes mellitus, and produces prompt prandial insulin responses with return to baseline insulin levels between meals. Nateglinide 0-11 insulin Homo sapiens 124-131 11030470-2 2000 Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (non-insulin-dependent) diabetes mellitus, and produces prompt prandial insulin responses with return to baseline insulin levels between meals. Nateglinide 0-11 insulin Homo sapiens 191-198 11030470-2 2000 Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (non-insulin-dependent) diabetes mellitus, and produces prompt prandial insulin responses with return to baseline insulin levels between meals. Nateglinide 0-11 insulin Homo sapiens 191-198 10877006-5 2000 RESULTS: Taken 10 min before meals, doses of 30-120 mg nateglinide caused dose-dependent increases in plasma insulin levels that were significantly greater than with placebo. Nateglinide 55-66 insulin Homo sapiens 109-116 10877006-11 2000 CONCLUSIONS: Nateglinide produced rapid, short-lived, dose-related increases in plasma insulin that significantly lowered mealtime glucose excursions compared with placebo with no incidence of hypoglycemia. Nateglinide 13-24 insulin Homo sapiens 87-94 10868832-5 2000 RESULTS: After a liquid meal challenge, nateglinide rapidly increased mealtime insulin levels within 30 min of drug intake and reduced mealtime glucose excursions without affecting triglyceride levels. Nateglinide 40-51 insulin Homo sapiens 79-86